Former Chief Financial Officer · Larimar Therapeutics, Inc. (LRMR)

Patricia Allen

FY2020 is the first fiscal year CompBrief holds for Patricia Allen as a named executive officer of Larimar Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,130,979

Salary $157,967Stock awards $0Bonus $229,770

4th of 4 named executive officers at Larimar Therapeutics by FY2020 total.

4 named officers on file for Larimar Therapeutics, FY2020

Patricia Allen’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Larimar Therapeutics’s whole pay program stands against its peers

  • Larimar Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on LRMR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 14, 2021 (DEF 14A).

Free

Get Patricia Allen’s full pay file as a PDF — free

More than this page: up to 10 years of Patricia’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Patricia Allen compensation by year

Larimar Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Larimar Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$157,967
Bonus$229,770
Stock awards$0
Option awards$0
Non-equity incentive$0
Pension and deferred compensation$0
All other$743,242
Total$1,130,979

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Larimar Therapeutics, Inc. DEF 14A filed April 14, 2021, accession 0001193125-21-115586, and prior-year filings.

How this page was built: the Larimar Therapeutics, Inc. filed document, accession 0001193125-21-115586. Every figure is read from that document and cited to the page and table it appears in. Filed April 14, 2021.

Larimar Therapeutics’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Carole Ben-MaimonPresident and Chief Executive Officer$5,270,178
Michael CelanoChief Financial Officer$1,790,739
Jeffrey HatfieldFormer Chief Executive Officer$1,351,638
Patricia Allen · this pageFormer Chief Financial Officer$1,130,979

The full Larimar Therapeutics compensation record

free company brief

This page is one person within Larimar Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Larimar Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Patricia Allen's compensation dossier · One-time report. No refunds.